Zobrazeno 1 - 10
of 818
pro vyhledávání: '"Thompson Alan J"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Health and Quality of Life Outcomes, Vol 9, Iss 1, p 80 (2011)
Abstract Background Intravenous steroids are routinely used to treat disabling relapses in multiple sclerosis (MS). Theoretically, the infusion could take place at home, rather than in hospital. Findings from other patient populations suggest that pa
Externí odkaz:
https://doaj.org/article/8881644791f340b9b2fff017c9bb2015
Autor:
Samson Rebecca S, Tozer Daniel J, Wheeler-Kingshott Claudia AM, Webber Daniel J, Barber Kelly, Richardson Karen, He Xiao-Ling, Crawley Charles, Scott Michael A, Patani Rickie, Kolappan Madhan, Connick Peter, Thomas David L, Du Ming-Qing, Luan Shi L, Michell Andrew W, Altmann Daniel R, Thompson Alan J, Miller David H, Compston Alastair, Chandran Siddharthan
Publikováno v:
Trials, Vol 12, Iss 1, p 62 (2011)
Abstract Background No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of trea
Externí odkaz:
https://doaj.org/article/6fe16c46d38a404dbd3a9ca26bebff26
Autor:
Thompson Alan J, Klein Martin, Hobart Jeremy C, Kragt Jolijn J, van der Linden Femke AH, van der Ploeg Henk M, Polman Chris H, Uitdehaag Bernard MJ
Publikováno v:
BMC Neurology, Vol 9, Iss 1, p 12 (2009)
Abstract Background This study examined whether MS patients and proxy respondents agreed on change in disease impact, which was induced by treatment. This may be of interest in situations when patients suffer from limitations that interfere with reli
Externí odkaz:
https://doaj.org/article/9a3a1b8ec5244e0692d04c093b6ea8b3
Autor:
Bhatia Kailash P, Thompson Alan J, Warner Thomas T, Cano Stefan J, Fitzpatrick Ray, Hobart Jeremy C
Publikováno v:
Health and Quality of Life Outcomes, Vol 6, Iss 1, p 58 (2008)
Abstract Background The United States Food and Drug Administration (FDA) are currently producing guidelines for the scientific adequacy of patient reported outcome measures (PROMs) in clinical trials, which will have implications for the selection of
Externí odkaz:
https://doaj.org/article/0500364126cb42089e07d24c6819ac84
Autor:
Thompson Alan J, Klein Martin, van Bon Margarethe, Kragt Jolijn J, van der Linden Femke AH, van der Ploeg Henk M, Polman Chris H, Uitdehaag Bernard MJ
Publikováno v:
BMC Neurology, Vol 8, Iss 1, p 2 (2008)
Abstract Background The use of self-report measurements in clinical settings is increasing. However, in patients with limitations that interfere with reliable self-assessment such as cognitive impairment or mood disturbances, as may be the case in mu
Externí odkaz:
https://doaj.org/article/d96d8aba46364c4da500241a52902296
Autor:
Amato, Maria Pia, Banwell, Brenda, Barkhof, Frederik, Chataway, Jeremy, Chitnis, Tanuja, Comi, Giancarlo, Derfuss, Tobias, Finlayson, Marcia, Goldman, Myla, Green, Ari, Hellwig, Kerstin, Kos, Daphne, Miller, Aaron, Mowry, Ellen, Oh, Jiwon, Salter, Amber, Sormani, Maria Pia, Tintore, Mar, Tremlett, Helen, Trojano, Maria, van der Walt, Anneke, Vukusic, Sandra, Waubant, Emmaunelle, Kuhlmann, Tanja *, Moccia, Marcello, Coetzee, Timothy *, Cohen, Jeffrey A *, Correale, Jorge *, Graves, Jennifer, Marrie, Ruth Ann *, Montalban, Xavier *, Yong, V Wee, Thompson, Alan J *, Reich, Daniel S *, *
Publikováno v:
In The Lancet Neurology January 2023 22(1):78-88